血清S-ChE PAB Apo A1及APACHEⅡ评分对重症肺炎预后的评估

doi:10.3969/j.issn.1006-6233.2018.04.004

摘要
图/表
参考文献
相关文章 (5)

全文: PDF (1321 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨血清胆碱酯酶(S-ChE)、前白蛋白(PAB)、载脂蛋白A1(Apo A1)及急性生理学与慢性健康状况系统Ⅱ(APACHEⅡ)评分对重症肺炎预后的评估作用。方法:选择2015年3月至2017年3月我院接诊的70例重症肺炎患者作为本研究对象,根据APACHEⅡ评分<20分为A组,APACHEⅡ评分≥20分为B组,比较两组多器官功能障碍综合征(MODS)发生率及病死率;根据是否发生MODS分为MODS组和非MODS组,根据28d后转归情况分为病死组和存活组,比较组间血清S-ChE、PAB、Apo A1及APACHEⅡ评分的差异。结果:A组MODS发生率、病死率均明显低于B组[17.24%(5/29)vs43.90%(18/41),10.34%(3/29)vs41.46%(17/41)](P<0.05);发生MODS组血清S-ChE、PAB、Apo A1明显低于非MODS组[(2.84±0.33)kU/L vs(4.53±0.40)kU/L,(118.45±15.20)mg/L vs(204.61±17.92)mg/L,(0.60±0.11)g/L vs(1.15±0.21)g/L],APACHEⅡ评分明显高于非MODS组[(26.91±2.74)分vs(19.58±2.04)分],比较均具有显著差异(P<0.05);病死组血清S-ChE、PAB、Apo A1明显低于存活组[(2.75±0.31)kU/L vs(4.46±0.29)kU/L,(109.86±15.73)mg/L vs(184.51±16.85)mg/L,(0.59±0.12)g/L vs(1.12±0.18)g/L],APACHEⅡ评分明显高于存活组[(28.95±2.40)分vs(18.58±1.97)分],比较均具有显著差异(P<0.05);Logistic回归分析结果中显示,S-ChE、PAB、Apo A1、APACHEⅡ评分均是影响重症肺炎预后的独立危险因素(OR=0.082、0.137、0.096、1.798,P均<0.05)。结论:血清S-ChE、PAB、Apo A1及APACHEⅡ评分对重症肺炎预后均具有良好的评估价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：重症肺炎, 胆碱酯酶, 前白蛋白, 载脂蛋白A1

Abstract：Objective: To study the evaluation of prognosis of severe pneumonia by serum cholinesterase (S-ChE), prealbumin(PAB), apolipoprotein A1 (Apo A1) and Acute physiology and chronic health scoring system II (APACHE II) score. Methods: 70 patients of severe pneumonia admitted in our hospital from March 2015 to March 2017 were selected as research objects. According to the APACHE score<20 divided into A group, APACHE score≥20 were divided into B group, the incidence of multiple organ dysfunction syndrome (MODS) and fatality rate were compared between the two groups; depending on whether MODS occurred divided into MODS and non MODS groups, according to the prognosis after 28d, the patients were divided into the fatality group and the survival group, the differences of serum S-ChE, PAB, Apo A1 and APACHE II scores between the two groups were compared. Results: The incidence of the MODS and fatality rate in Agroup were significantly lower than those in group B [17.24%(5/29) vs 43.90% (18/41), 10.34% (3/29) vs 41.46% (17/41)] (P<0.05); the serum S-ChE, PAB, Apo A1 in MODS group were significantly lower than those in non MODS group [(2.84±0.33)kU/L vs (4.53±0.40)kU/L, (118.45±15.20)mg/L vs (204.61±17.92)mg/L, (0.60±0.11)g/L vs (1.15±0.21)g/L], the APACHE score was higher than those in non MODS group [(26.91±2.74) score vs (19.58±2.04)score], the difference was statistically significant (P<0.05); the serum S-ChE, PAB, Apo A1 in fatality group were significantly lower than those in survival group [(2.75±0.31)kU/L vs (4.46±0.29)kU/L, (109.86±15.73)mg/L vs (184.51±16.85)mg/L, (0.59±0.12)g/L vs (1.12±0.18)g/L], the APACHE score was higher than those in survival group [(28.95±2.40) score vs (18.58±1.97) score], the difference was statistically significant (P<0.05); the Logistic regression analysis showed that the scores of S-ChE, PAB, Apo, A1 and APACHE II were independent risk factors for the prognosis of severe pneumonia (OR=0.082, 0.137, 0.096, 1.798, P<0.05). Conclusion: The serum S-ChE, PAB, Apo A1 and APACHE II scores have a good evaluation value in the prognosis of severe pneumonia.

Key words： Severe pneumonia Cholinesterase Prealbumin Apolipoprotein A1

基金资助:湖北省自然科技基金项目,(编号:2013CFC060)

引用本文:

江蓉, 刘建华, 徐内卫. 血清S-ChE PAB Apo A1及APACHEⅡ评分对重症肺炎预后的评估[J]. 河北医学, 2018, 24(4): 540-544.
JIANG Rong, et al. Evaluation of Prognosis of Severe Pneumonia by Serum S-ChE PAB Apo A1 and APACHE II Score. HeBei Med, 2018, 24(4): 540-544.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.04.004 或 http://www.hbyxzzs.cn/CN/Y2018/V24/I4/540

[1] 洪如钧,陈愉生,陈炆颖,等.重症监护病房重症肺炎患者危险因素及预后分析[J].福建医药杂志,2014,36(5):17~19.
[2] Li W, Ding C, Yin S. Severe pneumonia in the elderly: a multivariate analysis of risk factors[J]. Int Clin Exp Med, 2015, 8(8): 12463~12475.
[3] 杨永昌,贾志凌,樊卫红,等.降钙素原、C反应蛋白、前清蛋白及白细胞计数在重症肺炎诊断中的应用评价[J].国际检验医学杂志,2015,36(4):436~437.
[4] 莫新,吴志刚,吴伟博,等.重症肺炎患者早期血清胆碱酯酶含量的变化及其相关性探讨[J].热带医学杂志,2017,17(6):723~726,754.
[5] Zhang HW, Wei LY, Zhao G, et al. Periplaneta americana extract used in patients with systemic inflammatory response syndrome[J]. World Emerg Med, 2016, 7(1): 50~54.
[6] 李怀云.血清前白蛋白、C反应蛋白、载脂蛋白A1对重症肺炎患者生存状况的评估价值[J].安徽医药,2014,18(8):1517~1519.
[7] Akpinar S, Rollas K, et al. Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia[J].Thorac Dis, 2014, 6(7): 921~929.
[8] Perrone T, Quaglia F. Lung US features of severe interstitial pneumonia: case report and review of the literature[J].Ultrasound, 2017, 20(3): 247~249.
[9] Abbas M, Abbas Z. Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D[J]. World Hepatol, 2017, 9(22): 967~972.
[10] 莫新, 唐皓,曾丽金,等.血清胆碱酯酶含量对重症肺炎患者病情和预后的评估价值[J].中华危重病急救医学,2016,28(1):38~43.
[11] 陈晖,王丹,李亚明,等.血清前白蛋白动态变化评估重症社区获得性肺炎预后的价值[J].临床肺科杂志,2016,21(3):418~421.
[12] Bouharras-El Idrissi H, Molina-López J, et al. Prognostic value of severity by various visceral proteins in critically ill patients with SIRS during 7 days of stay[J]. Nutr Hosp, 2016, 33(6): 1276~1282.
[13] Johansson P, Almqvist EG, Bjerke M, et al. Reduced cerebrospinal fluid concentration of apolipoprotein A-I in patients with alzheimer's disease[J].Alzheimers Dis, 2017, 59(3): 1017~1026.
[14] 林化,马春林,王荣辉,等.血清前清蛋白、C反应蛋白及载脂蛋白A1对重症肺炎患者预后评估的价值[J].重庆医学,2014,43(5):529~531.
[15] 任艺,刘红梅,邵旦兵,等.MODS评分和APACHEⅡ评分对多脏器功能障碍综合征患者预后评价的比较[J].临床急诊杂志,2014,15(9):532~534.
[16] Khalid I, Alraddadi BM, Dairi Y, et al. Acute management and long-term survival among subjects with severe middle east respiratory syndrome coronavirus pneumonia and ARDS[J]. Respir Care, 2016, 61(3): 340~348.